ORPHA:300849
Diffuse large B-cell lymphoma of the central nervous system
Also known as: DLBCL of the CNS
Publications
1,143
Trials
6
Interventional, condition-specific
Researchers
1,422
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017596
- UMLS:C2026186
- NCIT:C71720
Additional Mondo synonyms (5)
CNS DLBCL · central nervous system diffuse large B-cell lymphoma · diffuse large B-cell lymphoma of central nervous system · primary DLBCL of the CNS · primary diffuse large B-cell lymphoma of the central nervous system
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,143 matched papers (925 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
6 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,143
1,143 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,143 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
925 in the last 10 years · low confidence
Phrase hits: 1,143 · MeSH hits: 0
Who's working on it?
1,422
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li Y9 papers · 2026
Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, P.R. China.
Papers in Europe PMC - 02Zhang Y9 papers · 2026
First Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, 300070, China.
Papers in Europe PMC - 03Wang Y8 papers · 2025
Tianjin Cancer Hospital, Tianjin Medical University, Tianjin, P.R. China.
Papers in Europe PMC - 04Li J7 papers · 2026
Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Papers in Europe PMC - 05Chen C6 papers · 2026
Department of Biostatistics, GoBroad Research Center, Leeza SOHO South Tower, Fengtai District, Beijing, 100073, China.
Papers in Europe PMC - 06Liu X5 papers · 2025
Department of Radiology, Laigang Hospital Affiliated to Taishan Medical University, Laiwu, Shandong, China (mainland).
Papers in Europe PMC - 07Miao Y5 papers · 2026
Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Papers in Europe PMC - 08
- 09Zhang X5 papers · 2026
School of Medicine, Nankai University, Tianjin, 300071, China.
Papers in Europe PMC - 10Guo Y4 papers · 2026
School of Biomedical Engineering, Tsinghua University, Beijing 100084, China. Electronic address: yongguo@tsinghua.edu.cn.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
6
interventional trials for this specific condition
6 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 1,017 trials are registered for diffuse large B-cell lymphoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
6 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 89th percentile).
low confidence · 89th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
6 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04609046·RECRUITING·Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Conditions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System·Matched via name phrase
- NCT07523737·RECRUITING·Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Conditions: Primary Central Nervous System Lymphoma (PCNSL) · Diffuse Large B Cell Lymphoma (DLBCL)·Matched via name phrase
Broader category: diffuse large B-cell lymphoma
1,017
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05281809·RECRUITING·Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Conditions: B-Cell Lymphoma · B Acute Lymphoblastic Leukemia · Diffuse Large B Cell Lymphoma · Mantle Cell Lymphoma·Matched via name phrase
- NCT04491370·RECRUITING·Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Conditions: B-cell Lymphoma · Burkitt Lymphoma · Diffuse Large B Cell Lymphoma · Follicular Lymphoma·Matched via name phrase
- NCT07507318·RECRUITING·Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Conditions: Diffuse Large B-Cell Lymphoma·Matched via name phrase
- NCT07570823·NOT YET RECRUITING·A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions: DLBCL - Diffuse Large B Cell Lymphoma·Matched via name phrase
- NCT06352242·RECRUITING·Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
Conditions: Diffuse Large B Cell Lymphoma·Matched via name phrase
- NCT07001540·RECRUITING·Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
Conditions: Diffuse Large B-Cell Lymphoma·Matched via name phrase
- NCT03676504·RECRUITING·Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Conditions: Acute Lymphoblastic Leukemia, Adult · Acute Lymphoblastic Leukemia, Pediatric · Chronic Lymphocytic Leukemia · Diffuse Large B Cell Lymphoma·Matched via name phrase
- NCT06569485·RECRUITING·A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
Conditions: DLBCL·Matched via name phrase
- NCT06570447·RECRUITING·Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Conditions: Diffuse Large B-Cell Lymphoma-Recurrent · Diffuse Large B-Cell Lymphoma-Refractory·Matched via name phrase
- NCT05641428·RECRUITING·Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
Conditions: NHL · DLBCL - Diffuse Large B Cell Lymphoma·Matched via name phrase
- NCT06830031·RECRUITING·Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Conditions: Diffuse Large B-cell-lymphoma · DLBCL, Nos Genetic Subtypes · Follicular Lymphoma Grade 3B · PMBL·Matched via name phrase
- NCT06977711·RECRUITING·Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
Conditions: Diffuse Large B-cell Lymphoma·Matched via name phrase
- NCT06652139·NOT YET RECRUITING·Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
Conditions: Diffuse Large B Cell Lymphoma·Matched via name phrase
- NCT07124936·RECRUITING·A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Conditions: Diffuse Large B Cell Lymphoma (DLBCL)·Matched via name phrase
- NCT07164469·NOT YET RECRUITING·Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Conditions: Large B-cell Lymphoma · Hodgkin Lymphoma·Matched via name phrase
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07147751·NOT YET RECRUITING·Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach
Conditions: Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)·Matched via name phrase
- NCT07188077·RECRUITING·Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Conditions: Primary Central Nervous System Lymphoma (PCNSL) · Diffuse Large B-Cell Lymphoma·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Diffuse large B-cell lymphoma of the central nervous system" OR "Diffuse large B-cell lymphoma of central nervous system" OR "DLBCL of the CNS" OR "DLBCL of CNS" OR "CNS DLBCL" OR "central nervous system diffuse large B-cell lymphoma" OR "primary DLBCL of the CNS" OR "primary DLBCL of CNS" OR "primary diffuse large B-cell lymphoma of the central nervous system" OR "primary diffuse large B-cell lymphoma of central nervous system"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Diffuse large B-cell lymphoma of the central nervous system" OR "Diffuse large B-cell lymphoma of central nervous system" OR "DLBCL of the CNS" OR "DLBCL of CNS" OR "CNS DLBCL" OR "central nervous system diffuse large B-cell lymphoma" OR "primary DLBCL of the CNS" OR "primary DLBCL of CNS" OR "primary diffuse large B-cell lymphoma of the central nervous system" OR "primary diffuse large B-cell lymphoma of central nervous system"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 6 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"diffuse large B-cell lymphoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1143) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T12:43:33.366Z
